Lactobacillus mucosae DPC 6426 as a bile-modifying and immunomodulatory microbe

Ryan, Paul M.; Stolte, Ellen H.; London, Lis E. E.; Wells, Jerry M.; Long, Sarah L.; Joyce, Susan A.; Gahan, Cormac G. M.; Fitzgerald, Gerald F.; Ross, R. Paul; Caplice, Noel M.; Stanton, Catherine

doi:10.1186/s12866-019-1403-0

UCC | UCC Library | IRIS

CORA Home

→
Research Institutes and Centres
→
APC Microbiome Institute
→
APC Microbiome Institute- Journal Articles
→
View Item

Show simple item record

dc.contributor.author	Ryan, Paul M.
dc.contributor.author	Stolte, Ellen H.
dc.contributor.author	London, Lis E. E.
dc.contributor.author	Wells, Jerry M.
dc.contributor.author	Long, Sarah L.
dc.contributor.author	Joyce, Susan A.
dc.contributor.author	Gahan, Cormac G. M.
dc.contributor.author	Fitzgerald, Gerald F.
dc.contributor.author	Ross, R. Paul
dc.contributor.author	Caplice, Noel M.
dc.contributor.author	Stanton, Catherine
dc.date.accessioned	2019-11-26T05:59:28Z
dc.date.available	2019-11-26T05:59:28Z
dc.date.issued	2019-02-08
dc.identifier.citation	Ryan, P.M., Stolte, E.H., London, L.E., Wells, J.M., Long, S.L., Joyce, S.A., Gahan, C.G., Fitzgerald, G.F., Ross, R.P., Caplice, N.M. and Stanton, C. (2019) 'Lactobacillus mucosae DPC 6426 as a bile-modifying and immunomodulatory microbe'. BMC microbiology, 19(1), 33. (13 pp.). DOI:10.1186/s12866-019-1403-0	en
dc.identifier.volume	19	en
dc.identifier.issued	1	en
dc.identifier.startpage	1	en
dc.identifier.endpage	13	en
dc.identifier.uri	http://hdl.handle.net/10468/9237
dc.identifier.doi	10.1186/s12866-019-1403-0	en
dc.description.abstract	Lactobacillus mucosae DPC 6426 has previously demonstrated potentially cardio-protective properties, in the form of dyslipidaemia and hypercholesterolemia correction in an apolipoprotein-E deficient mouse model. This study aims to characterise the manner in which this microbe may modulate host bile pool composition and immune response, in the context of cardiovascular disease. Lactobacillus mucosae DPC 6426 was assessed for bile salt hydrolase activity and specificity. The microbe was compared against several other enteric strains of the same species, as well as a confirmed bile salt hydrolase-active strain, Lactobacillus reuteri APC 2587.	en
dc.description.sponsorship	Enterprise Ireland Commercialisation Fund (grant number CF/2013/3030A/B); Teagasc (Walsh Fellowship Scheme)	en
dc.format.mimetype	application/pdf	en
dc.language.iso	en	en
dc.publisher	BMC part of Springer Nature	en
dc.relation.uri	https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-019-1403-0
dc.rights	© The Author(s). 2019	en
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/	en
dc.subject	Exopolysaccharide	en
dc.subject	Bile acid	en
dc.subject	Bile salt hydrolase (BSH)	en
dc.subject	Hypercholesterolaemia	en
dc.subject	CVD	en
dc.title	Lactobacillus mucosae DPC 6426 as a bile-modifying and immunomodulatory microbe	en
dc.type	Article (peer-reviewed)	en
dc.internal.authorcontactother	Catherine Stanton, APC Microbiome Ireland, University College Cork, Cork, Ireland. +353-21-490-3000 Email: catherine.stanton@ucc.ie	en
dc.internal.availability	Full text available	en
dc.description.version	Published Version	en
dc.contributor.funder	Teagasc	en
dc.contributor.funder	Seventh Framework Programme	en
dc.contributor.funder	Enterprise Ireland	en
dc.contributor.funder	Science Foundation Ireland	en
dc.description.status	Peer reviewed	en
dc.identifier.journaltitle	BMC Microbiology	en
dc.internal.IRISemailaddress	catherine.stanton@ucc.ie	en
dc.identifier.articleid	33	en
dc.relation.project	info:eu-repo/grantAgreement/EC/FP7::SP1::KBBE/289517/EU/Dietary Fibers supporting Gut and Immune Function - From polysaccharide compound to health claim/FIBEBIOTICS	en
dc.relation.project	info:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2273/IE/Alimentary Pharmabiotic Centre (APC) - Interfacing Food & Medicine/	en
dc.identifier.eissn	1471-2180